Functional imaging using computer methods to compare the effect of salbutamol and ipratropium bromide in patient-specific airway models of COPD

LA De Backer
Wg Vos
R Salgado
JW De Backer
A Devolder
SL Verhulst
R Claes
PR Germonpré
WA De Backer

1Department of respiratory Medicine, 2FluidDA, 3Department of radiology, Antwerp University hospital, Antwerp, Belgium

Background: Salbutamol and ipratropium bromide improve lung function in patients with chronic obstructive pulmonary disease (COPD). However, their bronchodilating effect has not yet been compared in the central and distal airways. Functional imaging using computational fluid dynamics offers the possibility of making such a comparison. The objective of this study was to assess the effects of salbutamol and ipratropium bromide on the geometry and computational fluid dynamics-based resistance of the central and distal airways.

Methods: Five patients with Global Initiative for Chronic Obstructive Lung Disease Stage III COPD were randomized to a single dose of salbutamol or ipratropium bromide in a crossover manner with a 1-week interval between treatments. Patients underwent lung function testing and a multislice computed tomography scan of the thorax that was used for functional imaging. Two hours after dosing, the patients again underwent lung function tests and repeat computed tomography.

Results: Lung function parameters, including forced expiratory volume in 1 second, vital capacity, overall airway resistance, and specific airway resistance, changed significantly after administration of each product. On functional imaging, the bronchodilating effect was greater in the distal airways, with a corresponding drop in airway resistance, compared with the central airways. Salbutamol and ipratropium bromide were equally effective at first glance when looking at lung function tests, but when viewed in more detail with functional imaging, hyporesponsiveness could be shown for salbutamol in one patient. Salbutamol was more effective in the other patients.

Conclusion: This pilot study gives an innovative insight into the modes of action of salbutamol and ipratropium bromide in patients with COPD, using the new techniques of functional imaging and computational fluid dynamics.

Keywords: chronic obstructive pulmonary disease, imaging, computed tomography, computational fluid dynamics, salbutamol, ipratropium

Introduction

Chronic obstructive pulmonary disease (COPD) is a heterogeneous disorder characterized by dysfunction of the small and large airways, as well as destruction of the lung parenchyma and its vasculature, in highly variable combinations. The hallmark of COPD is limitation of expiratory flow, which is slowly progressive and irreversible.1,2 Small airway function is still mainly evaluated using specific lung function tests, including flow-volume loops, nitrogen washout, and helium flow volume loops.3 Recently, there has been a trend towards the identification of new outcome parameters to evaluate...
The aim of this study was to compare the effects of salbutamol and ipratropium bromide at the level of all airways, especially in the distal and smaller airways. Recently developed functional imaging techniques offer the possibility to make these comparisons in detail and in a more sensitive way than is possible using the classical lung function tests. We compared these techniques in order to determine the most powerful method for assessment of bronchodilation in COPD.

Materials and methods

Patients

We recruited five patients with severe but stable COPD (three men and two women with Global Initiative for Chronic Obstructive Lung Disease [GOLD] Stage III disease). The degree of airway obstruction was verified by a baseline pulmonary function test after at least 12 hours of bronchodilator withdrawal. Lung function testing was performed according to European Respiratory Society guidelines. The study protocol was approved by the local ethics committee and each patient gave informed consent to all procedures. Baseline patient characteristics are given in Table 1.

Study design

The study was an open, randomized, two-way crossover, pilot study involving a screening visit and 2 study days.
separated by at least 1 week to avoid any carryover effect. Prior to the first dosing, patients underwent lung function testing (spirometry, body plethysmography) and low-dose, high-resolution CT scanning of the thorax. After dosing, the patients once more underwent lung function tests and low-dose, high-resolution CT scanning. These measurements were done 90 ± 30 minutes after the dose. The assessments on the second study day were the same as those done on the first day, except that the CT pre-dose was not taken to limit radiation exposure.

Study medication
The study medications, salbutamol and ipratropium bromide, were supplied by GlaxoSmithKline and Boehringer Ingelheim, respectively. The original medication and packaging were used. At each visit, the patients received either four puffs of salbutamol 100 µg or four puffs of ipratropium bromide 20 µg. The medication was administered by the investigator or by a member of the clinical unit designated by the investigator. Patients were trained to use the devices.

After gentle expiration, a dose of salbutamol 100 µg or ipratropium bromide 20 µg was inhaled in one breath to total lung capacity from a valved spacer device. The breath was then held for 5–10 seconds before the subject exhaled. Four separate doses (total dose 400 µg of salbutamol or 80 µg of ipratropium bromide) were delivered at 30-second intervals.

Inhaled corticosteroids were permitted during the study, provided that the dose remained constant for at least 6 weeks prior to the first visit and remained constant throughout the study period. An appropriate washout period for bronchodilating products was determined to be at least 24 hours for long-acting bronchodilators and at least 6 hours for short-acting bronchodilators prior to both study days.

CT and segmentation
High-resolution CT scans of the thorax can detect airways in the respiratory system down to the small airways with a diameter of 1–2 mm when imaged at total lung capacity. From high-resolution CT images, patient-specific values can be derived for the lumen cross-sectional area, airway length, airway wall thickness, and the extent of emphysema. These values can be assessed either in a particular plane or by analyzing multiple slices over a defined longitudinal region. These high-resolution CT scans enable three-dimensional reconstruction of the airway geometry regions to be developed. This geometry reconstruction is performed by semiautomatic segmentation of the airways. This involves identification and grouping of voxels that belong to a specific anatomic structure, including the airway tree, the lungs or lobes or, in some cases, the fissures. A three-dimensional reconstruction of the morphology can then be performed. Outcome parameters include lung volumes, lobar volumes, and local airway volumes. By assessing multiple scans of the same patient, it is possible to analyze the changes in different parameters either over time (eg, before and after bronchodilation), or at several breathing levels, such as forced residual capacity or total lung capacity.

In this study, at each CT data collection time point, two CT thorax scans were taken on a 64-slice GE LightSpeed VCT scanner. One scan was taken at total lung capacity, the other at functional residual capacity. Lung volumes were controlled using adapted spirometry during the high-resolution CT procedure. Scans were taken in a dose reduction protocol, ie, reduced tube voltage (100 kV) and tube current as a function of patient weight (1 mAs/kg). In addition to this, there was an increase in noise factor to reduce the radiation dose further. Total radiation dose for the high-resolution CT scans taken in this study per patient was less than 12 mSv. Scanning time was less than 5 seconds per scan, voxel dimension was approximately 0.5 mm², and the scanning region extended from the larynx down to the diaphragm.

From the high-resolution CT data, three-dimensional reconstruction of the airway geometry at total lung capacity was performed using semiautomatic segmentation of the airways up to the point where no distinction could be made between intraluminal and alveolar air (fifth to seventh bifurcation, airway diameter approximately 1 mm). In addition, the lung lobes were segmented both at total lung capacity and functional residual capacity by identifying the fissure planes and subsequently using these surfaces as cutting objects. By segmenting the lung lobes at two lung levels it was possible to assess lobar expansion and hence the internal patient-specific mass flow distribution in the lower airways. The segmentation and three-dimensional model reconstruction was performed using a commercially developed and validated software package (Mimics®, Materialise, Leuven, Belgium). To determine the local change in airway volume, the models were subdivided into individual branches according to the nomenclature defined by Ikeda (as described in Netter). For each individual airway branch, the volume (iVₐw) was determined before and after the administration of the medication.

Computational fluid dynamics
Functionality can be added to the static segmented images by applying computational fluid dynamics methods to characterize airway resistance and aerosol deposition patterns.
The postprocessing involves airway wall smoothing and reduction of segmentation artifacts. The airway model is then converted into a computational grid using a commercial software package (T-Grid®, Fluent Inc, Lebanon, NH) in order to solve the Navier-Stokes flow equations numerically. Flow is incompressible and isothermal, and most recent computational fluid dynamics models take into account the image-based internal flow distribution by including lobar expansion as a boundary condition. Computational fluid dynamics enables the determination of flow properties, including pressure, velocity, and density inside the entire flow domain. This allows the calculation of airway resistance by assessing the total pressure drop and airflow rate. Mesh size was around 4.5 × 10^6 cells. Steady flow simulations on these grids were performed using a commercial computational fluid dynamics solver (Fluent Inc). A mass flow of 30 L/minute was specified as the boundary condition at the trachea to reflect normal tidal breathing. At the outlets, the static pressure was defined using an iterative process to reflect the internal mass flow distribution matching the lobar expansion as derived from the CT data. The flow was considered laminar, incompressible, and adiabatic. Detailed descriptions of the segmentation and flow simulation procedures can be found in De Backer et al.24

From the computational fluid dynamics data, the $i_{Raw}$ was obtained. $i_{Raw}$ was defined as:

$$i_{Raw} = \frac{\Delta p}{F}$$

where $\Delta p$ is the total pressure drop over a certain region and $F$ is the mass flow rate of air through this region.

### Statistical analysis

Comparisons of airway characteristics before and after medication, as well as changes in airway characteristics between both medications, were assessed using the Wilcoxon matched-pairs test.

Comparisons between pulmonary function tests and functional imaging were made using Spearman rank correlations. For all analyses, $P < 0.05$ was defined as statistically significant and $P < 0.1$ as a trend. Analyses were performed using Statistica® software (StatSoft, Sandton, South Africa).

## Results

All five patients completed the study. The patients (three male and two female, mean age 67 years) had GOLD Stage III COPD, a mean 71 pack-year smoking history, and an average FEV₁ of 35% predicted (Tables 1 and 2). A detailed overview of the results and the abbreviations used can be found in Table 3 and Figures 1–3.

For these five patients, there was a significant increase in vital capacity ($P = 0.04$) and decrease in airway resistance ($R_{aw}$, $P = 0.04$) and specific resistance ($sR_{aw}$, $P = 0.04$) 1.5 hours after inhalation of salbutamol. Functional imaging parameters showed an increase in total airway volume ($iV_{awtot}$, $P = 0.04$) after salbutamol, with a small rise in $iV_{awcent}$ ($P = 0.08$) and a large rise in $iV_{awdist}$ ($P = 0.04$). Also, after salbutamol, $iR_{awtot}$ decreased ($P = 0.04$) due to a reduction in $iR_{awcent}$ ($P = 0.08$) and $iR_{awdist}$ ($P = 0.08$).

After ipratropium bromide, there was a rise in FEV₁ ($P = 0.04$) and a trend towards an increase in vital capacity ($P = 0.08$), and a decrease in $R_{aw}$ ($P = 0.08$) and $sR_{aw}$ ($P = 0.08$). Functional imaging parameters show an increase in $iV_{awtot}$ ($P = 0.04$), with a small rise in $iV_{awcent}$ ($P = 0.04$) and a large rise in $iV_{awdist}$ ($P = 0.04$). Also, after ipratropium bromide, $iR_{awtot}$ decreased ($P = 0.04$) due to a decrease in $iR_{awcent}$ ($P = 0.08$) and $iR_{awdist}$ ($P = 0.08$).

No significant differences were found between changes in lung function testing and functional imaging parameters.

### Table 2 Baseline lung function values in individual patients

<table>
<thead>
<tr>
<th>Patient</th>
<th>Age (years)</th>
<th>FEV₁ pre (%)</th>
<th>FEV₁ post-BD (%)</th>
<th>FEV₁ post-BD (L)</th>
<th>VC (L)</th>
<th>FEV₁/VC</th>
<th>TLC (L)</th>
<th>FRC (L)</th>
<th>$R_{aw}$</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>66</td>
<td>31</td>
<td>35</td>
<td>0.73</td>
<td>1.95</td>
<td>34</td>
<td>7.14</td>
<td>5.87</td>
<td>1.04</td>
</tr>
<tr>
<td>2</td>
<td>65</td>
<td>34</td>
<td>34</td>
<td>0.91</td>
<td>2.16</td>
<td>43</td>
<td>4.92</td>
<td>4</td>
<td>1.12</td>
</tr>
<tr>
<td>3</td>
<td>76</td>
<td>31</td>
<td>37</td>
<td>0.71</td>
<td>1.24</td>
<td>48</td>
<td>4.91</td>
<td>3.59</td>
<td>1.409</td>
</tr>
<tr>
<td>4</td>
<td>65</td>
<td>25</td>
<td>33</td>
<td>1.07</td>
<td>3.63</td>
<td>22</td>
<td>9.19</td>
<td>7.28</td>
<td>1.02</td>
</tr>
<tr>
<td>5</td>
<td>61</td>
<td>33</td>
<td>36</td>
<td>0.98</td>
<td>2.92</td>
<td>30</td>
<td>6.99</td>
<td>4.82</td>
<td>1</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>Patient</th>
<th>RV (L)</th>
<th>IC (L)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>5.19</td>
<td>1.35</td>
</tr>
<tr>
<td>2</td>
<td>2.76</td>
<td>1.01</td>
</tr>
<tr>
<td>3</td>
<td>3.67</td>
<td>1.04</td>
</tr>
<tr>
<td>4</td>
<td>5.55</td>
<td>1.92</td>
</tr>
<tr>
<td>5</td>
<td>4.07</td>
<td>1.73</td>
</tr>
</tbody>
</table>

**Abbreviations:** BD, bronchodilator; RFC, residual functional capacity; RV, residual volume; IC, inspiratory capacity; FEV₁, forced expiratory volume in 1 second; TLC, total lung capacity; VC, vital capacity; $R_{aw}$, airway resistance
Table 3 Lung function changes after salbutamol and ipratropium bromide

<table>
<thead>
<tr>
<th>Patient number</th>
<th>ΔFEV1 (% pred)</th>
<th>ΔFEV1 (% pred)</th>
<th>ΔVC (L)</th>
<th>ΔVC (L)</th>
<th>ΔR (kPa/L)</th>
<th>ΔR (kPa/L)</th>
<th>ΔspecR (kPa)</th>
<th>ΔspecR (kPa)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>4</td>
<td>6</td>
<td>0.22</td>
<td>0.37</td>
<td>-0.120</td>
<td>-0.260</td>
<td>-1.44</td>
<td>-1.59</td>
</tr>
<tr>
<td>2</td>
<td>0</td>
<td>1</td>
<td>0.23</td>
<td>-0.01</td>
<td>-0.161</td>
<td>0.089</td>
<td>-1.00</td>
<td>0.19</td>
</tr>
<tr>
<td>3</td>
<td>6</td>
<td>4</td>
<td>0.28</td>
<td>0.27</td>
<td>-0.479</td>
<td>-0.201</td>
<td>-2.06</td>
<td>-0.91</td>
</tr>
<tr>
<td>4</td>
<td>8</td>
<td>6</td>
<td>0.55</td>
<td>0.54</td>
<td>-0.560</td>
<td>-0.461</td>
<td>-4.46</td>
<td>-3.38</td>
</tr>
<tr>
<td>5</td>
<td>3</td>
<td>6</td>
<td>0.04</td>
<td>0.20</td>
<td>-0.171</td>
<td>-0.339</td>
<td>-0.89</td>
<td>-1.51</td>
</tr>
<tr>
<td>Average</td>
<td>4.2</td>
<td>3.6</td>
<td>0.26</td>
<td>0.27</td>
<td>-0.298</td>
<td>-0.234</td>
<td>-1.97</td>
<td>-1.44</td>
</tr>
</tbody>
</table>

<table>
<thead>
<tr>
<th>ΔVtot (%)</th>
<th>ΔVcent (%)</th>
<th>ΔVdist (%)</th>
<th>ΔVtot (%)</th>
<th>ΔVcent (%)</th>
<th>ΔVdist (%)</th>
<th>ΔR cent (%)</th>
<th>ΔR cent (%)</th>
<th>ΔR dist (%)</th>
</tr>
</thead>
<tbody>
<tr>
<td>1</td>
<td>18.1</td>
<td>9.9</td>
<td>3.7</td>
<td>38.8</td>
<td>19.9</td>
<td>-44</td>
<td>-19</td>
<td>-30</td>
</tr>
<tr>
<td>2</td>
<td>11.1</td>
<td>8.0</td>
<td>5.7</td>
<td>39.9</td>
<td>20.8</td>
<td>-55</td>
<td>-41</td>
<td>-15</td>
</tr>
<tr>
<td>3</td>
<td>19.6</td>
<td>10.9</td>
<td>10.0</td>
<td>80.6</td>
<td>43.7</td>
<td>-63</td>
<td>-56</td>
<td>-8</td>
</tr>
<tr>
<td>4</td>
<td>0.7</td>
<td>17.6</td>
<td>-3.0</td>
<td>5.4</td>
<td>15.8</td>
<td>-27</td>
<td>-64</td>
<td>24</td>
</tr>
<tr>
<td>5</td>
<td>9.4</td>
<td>4.5</td>
<td>6.8</td>
<td>0.9</td>
<td>15.9</td>
<td>-34</td>
<td>-31</td>
<td>-37</td>
</tr>
<tr>
<td>Average</td>
<td>10.8</td>
<td>10.5</td>
<td>5.0</td>
<td>4.5</td>
<td>31.6</td>
<td>32.4</td>
<td>-47.6</td>
<td>-44.5</td>
</tr>
</tbody>
</table>

**Abbreviations:** FEV1, forced expiratory volume in 1 second; VC, vital capacity; R, airway resistance; specR, specific airway resistance (corrected for lung volume R × FRC); Vtot, total volume of the segmented airways; Vcent, volume of the central airways until the third bifurcation; Vdist, volume of the distal airways from third to seventh bifurcation; Rcent, airway resistance of all segmented airways; Rcent, airway resistance on the central airways until the third bifurcation; Rdist, airway resistance of the distal airways from third to seventh bifurcation; % pred, percentage predicted.

**Notes:** Grey shading indicates changes after salbutamol; no shading indicates changes after ipratropium bromide.
Figure 1 Changes in airway volume based on segmented airways from the CT scan (\(iV_t\)) in a patient (upper figures) mainly responsive to salbutamol (B) and less to ipratropium bromide (A), and in a patient (lower figures) more responsive to ipratropium bromide (C) and less responsive to salbutamol (D).

Figure 2 Changes in FEV\(_1\), VC, Raw and s\(R_{aw}\) after salbutamol and ipratropium in five COPD patients (GOLD III). All changes are significant (\(P < 0.05\)) except the changes in FEV\(_1\) after salbutamol and VC after ipratropium.

Abbreviations: FEV\(_1\), forced expiratory volume in 1 second; VC, vital capacity; SE, standard error; SD, standard deviation.
after salbutamol or after ipratropium bromide. Looking at the functional imaging parameters, we noticed a trend towards a higher response to salbutamol. However, for one patient, we observed an inverse trend, with hyporeactivity to salbutamol. Repeating the statistical analysis without this hyporesponder to salbutamol, we obtain a trend in favor of salbutamol (comparing with ipratropium bromide). However, ipratropium bromide was more active in some patients, especially when changes in airways caliber were higher response to salbutamol. However, for one patient, we observed an inverse trend, with hyporeactivity to salbutamol. Repeating the statistical analysis without this hyporesponder to salbutamol, we obtain a trend in favor of salbutamol (comparing with ipratropium bromide). However, ipratropium bromide was more active in some patients, especially when changes in airways caliber were hyporeactive to salbutamol.

**Discussion**

Using functional imaging, we demonstrated that central but mainly distal airway dimensions (third to seventh bifurcation) increased significantly after an inhaled beta₂-agonist (salbutamol) and anticholinergic agent (ipratropium bromide) in patients with severe COPD. Corresponding changes in lung function (spirometry, airway resistance) could be observed, but the changes seen on lung function testing were overall less pronounced than the changes in airway caliber seen by the imaging method. The changes observed with imaging were even greater when airway resistance calculated using computational fluid dynamics was taken into consideration. The latter method seems to provide added, more pronounced, and more sensitive information in the calculation of airway dimensions. Also, discrepancies between FEV₁ and forced vital capacity responses were observed, with more pronounced overall volume responses. Overall, the response to salbutamol was more pronounced than that to ipratropium bromide. However, ipratropium bromide was more active in one patient, especially when changes in airways caliber were taken into account.

Assessment of reversibility is recognized as an essential part of the management of airway obstruction. COPD patients are considered to have airflow limitation that is not fully reversible. While some patients can still show high reversibility, most COPD patients have limited changes in FEV₁ after bronchodilators. Some can show larger changes in forced vital capacity and develop the so-called...
volume response, which is seen more in severe patients with end-expiratory flow limitation. We focused on the more common, severe COPD patients with little reversibility in FEV after bronchodilators. The functional imaging used in this study provided us with the opportunity to see whether changes in airway caliber and calculated airway resistance using computer methods were comparable with the limited changes seen in FEV in these patients. Moreover, the imaging method used provided information on changes in both central (until the third bifurcation) and distal (third to seventh bifurcation) airways. High-resolution CT has been used previously to determine bronchodilator responses either looking at changes in parenchymal density or at bronchus–vessel caliber relationship. Both methods are more indirect than the segmentation method used in this study complemented with computational fluid dynamics-based airway resistance measurements. We did not calculate emphysema scores for these patients, but we know from as yet unpublished data that functional imaging can be of value in doing this, because we can measure blood vessel density in every lobe and compare this with the percentage of airflow going to this lobe. This way, we have an idea about the ventilation/perfusion match. We certainly have to include this technique in a larger study in the future.

The variable response to different bronchodilators in COPD patients has been observed before, and previous attempts to identify the right patients for certain products were not satisfying. Oga et al found that the effects of different bronchodilators on exercise capacity varied among individuals with stable COPD, while the degree of bronchodilation measured by FEV did not correlate with the increase in endurance time of the exercise test. This suggests that FEV is not an optimal descriptor of the bronchodilator effect. We did not measure diffusing capacity of the lung for carbon monoxide or maximum inspiratory and expiratory pressure in this study, which could be interesting to compare in larger studies in the future, as would be the BODE index (we did not measure the 6-minute walking distance), because it is a global measure of COPD severity, which takes into account some important health-related quality of life measures.

We found that the response to salbutamol was larger in four out of five of our patients compared with the response to ipratropium bromide. However, a hyporesponse to salbutamol was observed for one patient. Classical lung function testing was not able to make this distinction. FEV clearly underestimates the acute bronchodilator effects in COPD patients, probably because the main effect is situated in the distal airways, as we see with imaging.

In this study, we used functional imaging as a method for evaluating bronchodilator treatment in COPD. Because COPD is such a heterogeneous disease, the same treatment does not have the same effect in different patients. This method helps us to understand why this is the case. It is the first method to evaluate regional resistances and volumes, and gives us new insights into the mechanism of bronchodilating treatment. It could help us to select the right treatment for the right patient, which should be the goal of every physician.

Suboptimal dosing may contribute to the wide variation of responders with different degrees of reversibility, because dose-response relationships have been demonstrated. Using higher doses, there is no substantial difference between using a short-acting beta-agonist or a short-acting muscarinic agonist. It has also been demonstrated that there is an effective improvement in FEV on adding a high dose of salbutamol (600 µg) or a high dose of ipratropium bromide (120 µg) to regular tiotropium. A limitation of this study is the fact that we only studied patients with more severe GOLD Stage III COPD who are known to have more volume response. Additional insight could be gained by performing the same tests on patients with GOLD Stage I, II, and IV COPD.

Different descriptors of the disease, like genetics and emphysema scores, might also be of help in predicting response. Some studies have shown that genotype may determine the bronchodilating response. A larger study including all degrees of severity and performed over a longer time period could also give important information on the relationship between clinical outcomes (quality of life, dyspnea scores) and imaging data. We can conclude that salbutamol and ipratropium bromide have a bronchodilating effect in COPD patients, as indicated by a significant improvement in FEV, vital capacity, R, and sR in

### Table 5: Spearman rank comparison between change in pulmonary function test volumes and change in functional imaging volumes

<table>
<thead>
<tr>
<th></th>
<th>ΔV&lt;sub&gt;FEV1&lt;/sub&gt;</th>
<th>ΔV&lt;sub&gt;centr&lt;/sub&gt;</th>
<th>ΔV&lt;sub&gt;distr&lt;/sub&gt;</th>
</tr>
</thead>
<tbody>
<tr>
<td>ARV (L)</td>
<td>-0.04</td>
<td>0.08</td>
<td>0.26</td>
</tr>
<tr>
<td>P</td>
<td>0.3</td>
<td>0.5</td>
<td>0.3</td>
</tr>
<tr>
<td>ARV (%)</td>
<td>-0.46</td>
<td>-0.26</td>
<td>-0.39</td>
</tr>
<tr>
<td>P</td>
<td>0.2</td>
<td>0.5</td>
<td>0.3</td>
</tr>
</tbody>
</table>

**Abbreviations:** RV, residual volume; FrC, functional residual capacity; Vtot, total volume of the segmented airways; Vcentr, volume of the central airways until the third bifurcation.
classical lung function testing. Using functional imaging, regional differences in airway volumes and resistances can be detected after bronchodilation. Distal broncholiration is more pronounced than central broncholiration. \( R_{\text{awt}} \) decreases, with a redistribution of airway resistance from the distal to the central airways. From classical lung function tests, there seems to be no difference in efficiency between salbutamol and ipratropium bromide. Nevertheless, using functional imaging parameters, we can distinguish two different types of responders, ie, the ones who respond more to salbutamol and a possible subgroup of hyporesponders to salbutamol. To confirm these findings, we need to study a larger group of patients, looking at different characteristics to predict and explain these different responses.

**Disclosure**

The authors report no conflicts of interest in this work.

**References**
